Literature DB >> 27246630

Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.

Ugur Uslu1, Gerold Schuler1, Jan Dörrie1, Niels Schaft2.   

Abstract

The adoptive transfer of engineered T cells represents an important approach in immunotherapy of melanoma. However, relapse of the tumor can occur due to immune-escape mechanisms developed by the tumor cells, for example antigen loss, downregulation of the major histocompatibility complex presentation machinery and defects in antigen processing. To counteract these mechanisms, we combined a T-cell receptor and a chimeric antigen receptor, specific for different common melanoma antigens, gp100 (PMEL) and MCSP (HMW-MAA), to generate functional CD8+ T cells expressing two additional receptors (TETARs) by electroporation of receptor-encoding mRNA. These TETARs produced cytokines and were lytic upon recognition of each of their cognate antigens, while no reciprocal inhibition of the receptors occurred. When stimulated with target cells, which express both antigens, an enhanced effect was suggested. The confirmation that chimeric antigen receptors and T-cell receptors can be functionally combined opens up new avenues in cancer immunotherapy, and the generation of TETARs helps by-passing major mechanisms by which tumor cells escape immune recognition.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adoptive T-cell therapy; cancer; human; immune escape; immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27246630     DOI: 10.1111/exd.13095

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  9 in total

Review 1.  Tumor buster - where will the CAR-T cell therapy 'missile' go?

Authors:  Chunrun Qu; Hao Zhang; Hui Cao; Lanhua Tang; Haoyang Mo; Fangkun Liu; Liyang Zhang; Zhenjie Yi; Lifu Long; Luzhe Yan; Zeyu Wang; Nan Zhang; Peng Luo; Jian Zhang; Zaoqu Liu; Weijie Ye; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-10-19       Impact factor: 41.444

2.  RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.

Authors:  Fernanda Pohl-Guimarães; Changlin Yang; Kyle A Dyson; Tyler J Wildes; Jeffrey Drake; Jianping Huang; Catherine Flores; Elias J Sayour; Duane A Mitchell
Journal:  Mol Ther       Date:  2018-10-17       Impact factor: 11.454

3.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

Review 4.  CSPG4: a prototype oncoantigen for translational immunotherapy studies.

Authors:  Valeria Rolih; Giuseppina Barutello; Selina Iussich; Raffaella De Maria; Elena Quaglino; Paolo Buracco; Federica Cavallo; Federica Riccardo
Journal:  J Transl Med       Date:  2017-07-01       Impact factor: 5.531

Review 5.  T-cell receptor-engineered T cells for cancer treatment: current status and future directions.

Authors:  Yu Ping; Chaojun Liu; Yi Zhang
Journal:  Protein Cell       Date:  2017-01-20       Impact factor: 14.870

Review 6.  Targeting cancers through TCR-peptide/MHC interactions.

Authors:  Qinghua He; Xianhan Jiang; Xinke Zhou; Jinsheng Weng
Journal:  J Hematol Oncol       Date:  2019-12-18       Impact factor: 17.388

7.  The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Authors:  Bianca Simon; Manuel Wiesinger; Johannes März; Kilian Wistuba-Hamprecht; Benjamin Weide; Beatrice Schuler-Thurner; Gerold Schuler; Jan Dörrie; Ugur Uslu
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

Review 8.  In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.

Authors:  Thangavelu Soundara Rajan; Agnese Gugliandolo; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-09-06       Impact factor: 5.923

Review 9.  RNA-electroporated T cells for cancer immunotherapy.

Authors:  Fernanda Pohl-Guimarães; Lan B Hoang-Minh; Duane A Mitchell
Journal:  Oncoimmunology       Date:  2020-10-07       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.